- POSITIVE
Annual Revenue Sunrest Lifescience Mar-2026 Annual Revenue is Rs 33 Cr which is growth of 0.4% YoY.
- POSITIVE
Annual Net Profit Sunrest Lifescience Mar-2026 Annual Net Profit is Rs 3 Cr which is growth of 54.4% YoY.
NSE: SUNREST
Sunrest Lifescience Live Share Price Today, Share Analysis and Chart
aboutSunrest Lifescience Ltd. is a pharmaceutical company that operates primarily through a third-party manufacturing model to market and distribute a range of healthcare products. The company focuses on pharmaceutical formulations such as tablets, ca... Read More
37.30-1.95(-4.97%)
1,600
NSE Volume
NSE 02 Nov, 2026 3:31 PM (IST)
Please subscribe to view forecaster data
Sunrest Lifescience Stock Price Analysis
Day Price Range-5.0% 1 Day return | 37.3 (LTP) 37.337.3 LowHigh |
|---|---|
Week Price Range11.3% 1 Week return | 37.3 (LTP) 35.740 LowHigh |
Month Price Range5.1% 1 Month return | 37.3 (LTP) 3040.4 LowHigh |
52 Week Price Range-8.5% 1 Year return | 37.3 (LTP) 24.645 LowHigh |
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Sunrest Lifescience annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 |
|---|---|---|---|---|---|---|---|---|---|
10.5% | 14.4% | 33.3 | 33.1 | 29.5 | 24.7 | 26.9 | 17 | ||
Operating Exp. Ann. | 9.2% | 11.2% | 28.4 | 30.1 | 28.8 | 21.8 | 25.8 | 16.7 | |
Operating Profit Ann. | 18.3% | 74.1% | 4.8 | 3 | 0.7 | 2.9 | 1.1 | 0.3 | |
OPM Ann. % | 7.9% | 56% | 14.50% | 9.06% | 2.34% | 11.53% | 4.04% | 1.57% | |
10.1% | 11.8% | 29.2 | 30.5 | 28.9 | 21.9 | 25.9 | 16.7 | ||
EBITDA Ann. | 18.3% | 74.1% | 4.8 | 3 | 0.7 | 2.9 | 1.1 | 0.3 | |
EBITDA Ann. margin % | 7.6% | 56% | 14.51% | 9.06% | 2.34% | 11.65% | 4.13% | 1.57% | |
Interest Ann. | - | - | 0.5 | 0.3 | |||||
Depr. | 26% | - | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | |
PBT Ann. | 14.9% | 83% | 4.1 | 2.6 | 0.6 | 2.7 | 1.1 | 0.2 | |
Tax Ann. | 12.6% | 58.5% | 1 | 0.6 | 0.4 | 0.7 | 0.3 | 0.1 | |
15.7% | 73% | 3.1 | 2 | 0.2 | 2 | 0.8 | 0.2 | ||
Net Profit Ann. | 15.7% | 73% | 3.1 | 2 | 0.2 | 2 | 0.8 | 0.2 | |
NPM Ann. % | 3.8% | 57.1% | 9.28% | 6.03% | 0.76% | 8.29% | 2.89% | 0.97% | |
EPS Adj. latest Ann. | 14.5% | 78.3% | 3.6 | 2.3 | 0.3 | 2.4 | 0.9 | 0.2 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
0.6%
2Y CAGR
6.2%
3Y CAGR
10.5%
5Y CAGR
14.4%
Total Revenue Annual growth is lower than historical averages.
Net Profit Ann.
1Y CHG
55%
2Y CAGR
293.7%
3Y CAGR
15.7%
5Y CAGR
73%
Net Profit Annual growth is stable compared to historical averages.
Operating Exp. Ann.
1Y CHG
-5.6%
2Y CAGR
-0.7%
3Y CAGR
9.2%
5Y CAGR
11.2%
Operating Expenses Annual Cr is falling faster than historical averages.
Sunrest Lifescience Technical Analysis
Sunrest Lifescience EMA & SMA
Bullish+6
7 bullish, 1 bearish
Bullish7
Bearish1
| 5 Day | 36.8 |
|---|---|
| 10 Day | 36.6 |
| 12 Day | 36.7 |
| 20 Day | 36.9 |
| 26 Day | 37 |
|---|---|
| 50 Day | 36.9 |
| 100 Day | 36.7 |
| 200 Day | 38.7 |
Sunrest Lifescience Delivery And Volume
Daily Avg. Delivery Volume %
02 Nov, 2026100.0%
Week88.9%
Month-
Sunrest Lifescience Active Candlesticks
Inside Uptrend Short Line Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Sunrest Lifescience Resistance and Support
37.30
Pivot
| First Resistance | 37.3 |
|---|---|
| Second Resistance | 37.3 |
| Third Resistance | 37.3 |
| First Support | 37.3 |
|---|---|
| Second Support | 37.3 |
| Third Support | 37.3 |
| Day RSI | 50.6 |
|---|---|
| Day MACD | -0.3 |
| Day MFI | 59 |
| Day MACD Signal Line | -0.4 |
Sunrest Lifescience Beta
| 1 Month | -0.8 |
|---|---|
| 1 Year | -0.6 |
| 3 Month | 0.1 |
|---|---|
| 3 Year | - |
Sunrest Lifescience Price Change Analysis
↑5.1%
Over 1 Month
LowHigh
30.140.4
↑9.6%
Over 3 Months
LowHigh
30.145
↑10.9%
Over 6 Months
LowHigh
30.045
↓-8.5%
Over 1 Year
LowHigh
24.645
Sunrest Lifescience Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| KHUSHBOO ASHISH JAIN | Bulk | Sell | 27 Mar 2026 | 37.83 | 22,400 | NSE |
| KHUSHBOO ASHISH JAIN | Bulk | Purchase | 27 Mar 2026 | 36.50 | 9,600 | NSE |
| RELIGO CAPITAL ADVISORS PRIVATE LIMITED | Bulk | Sell | 18 Feb 2026 | 42 | 32,000 | NSE |
| ABHISHEK NIRMAL JAIN | Bulk | Purchase | 18 Feb 2026 | 41.89 | 33,600 | NSE |
| POOJA RAHUL SHAH | Bulk | Sell | 13 Nov 2025 | 49.64 | 48,000 | NSE |
| AMIT R AGARWAL | Bulk | Purchase | 13 Nov 2025 | 49.64 | 52,800 | NSE |
| KHUSHBOO ASHISH JAIN | Bulk | Sell | 29 Oct 2025 | 50 | 41,600 | NSE |
| RELIGO CAPITAL ADVISORS PRIVATE LIMITED | Bulk | Purchase | 29 Oct 2025 | 49.93 | 43,200 | NSE |
| BHARATKUMAR VARDHILAL THAKKAR | Bulk | Sell | 23 Sep 2025 | 44 | 44,800 | NSE |
| NIKHILKUMAR YASHVNTLAL THAKKAR | Bulk | Sell | 23 Sep 2025 | 44.18 | 27,200 | NSE |
Sunrest Lifescience Corporate Actions
Sunrest Lifescience Board Meetings
Sunrest Lifescience past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
112 Aug 2026 | Others | To consider other business matters |
204 Aug 2026 | Fund Raising & Others | To consider Fund Raising and other business matters (Revised) |
326 Jun 2026 | Fund Raising & Others | To consider other business matters. |
429 May 2026 | Audited Results | - |
516 Mar 2026 | Fund Raising & Others | (Revised) To consider other business matters. |
Sunrest Lifescience Rights issue
Sunrest Lifescience rights issue history, along with record, ex-rights dates, and rights ratios.
#Ex-Date | Ratio | Face Value | Premium | Record Date |
|---|---|---|---|---|
110 Aug 2026 | 1.0:1.0 | 10 | 25 | 10 Aug 2026 |
223 Mar 2026 | 1.0:1.0 | 10 | 25 | 23 Mar 2026 |
Sunrest Lifescience - Company Profile
Sunrest Lifescience Management Structure
Sunrest Lifescience management structure with salaries, total experience, and qualifications.
Sunrest Lifescience Board of Directors
Sunrest Lifescience Board of directors with salaries, total experience, and qualifications.
Website: www.sunrestlifescience.com
About the company - Business Profile
Sunrest Lifescience Ltd. is a pharmaceutical company that operates primarily through a third-party manufacturing model to market and distribute a range of healthcare products. The company focuses on pharmaceutical formulations such as tablets, capsules, ointments, and injectables, catering to diverse therapeutic segments.
Key Points
- Key Facts:
- Founded: Incorporated in 2017.
- Headquarters: Ahmedabad, Gujarat.
- Stock Listing: Listed on the NSE SME platform following its Initial Public Offer (IPO) in November 2023.
- Product Categories: Over-the-counter (OTC) and prescription-based drugs including anti-bacterial, anti-diabetic, dental cure, and anti-hypertensive medications.
- Operations and Business Model:
- The company follows an asset-light business model, where it does not own manufacturing facilities but outsources production to third-party manufacturers.
- This model allows the company to focus on its core competencies: marketing, distribution, and product selection.
- Sunrest acquires trademarks or enters into agreements with manufacturers to sell products under its own brand name.
- Financial Performance:
- Revenue from Operations: For the fiscal year ended March 31, 2023, the company reported revenue of ₹2,467.43 Lakhs.
- Net Profit: The profit after tax (PAT) for FY2023 stood at ₹204.38 Lakhs, showing significant growth compared to ₹68.61 Lakhs in FY2022.
- Revenue Breakdown: The business is primarily domestic, with high concentrations of sales in states like Gujarat and Maharashtra.
- Key Products and Market Presence:
- Maintains a portfolio of approximately 18 to 20 registered trademarks.
- Product range includes specialized therapeutic segments such as Gynaecology, Dental, and Multi-vitamins.
- Future Outlook: The company intended to use IPO proceeds to meet working capital requirements and for general corporate purposes to expand its product footprint in the Indian market.
- Sustainability and Governance:
- The company is managed by promoters Mr. Nital Shah and Mr. Amit Thakkar, who have over two decades of experience in the pharmaceutical industry.
- Strategic initiatives focus on deepening market penetration through a network of over 35-40 distributors and a dedicated field force.
- Employee and Organizational Details:
- As per the IPO prospectus, the company operates with a lean team, primarily consisting of sales and administrative staff to manage its distribution-led model.
- No major subsidiaries were reported during its initial public listing phase.